MJN-26710-47632
4 vaccinations
11 coded responses
41 check-ins
10 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 372 / TN
- Registered
- 2020-12-17
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2020-12-17
Registered in v-safe
-
2020-12-20
Dose 1 — Pfizer-BioNTech
-
2020-12-21
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Fever · Chills, Fatigue or tirednessAdult check-in
- 2020-12-22
- 2020-12-23
- 2020-12-24
- 2020-12-27
- 2021-01-03
-
2021-01-10
Dose 2 — Pfizer-BioNTech
- 2021-01-19
- 2021-01-24
- 2021-01-31
- 2021-02-09
- 2021-02-14
- 2021-02-21
- 2021-04-11
- 2021-07-11
-
2021-09-28
Dose 3 — Pfizer-BioNTechCo-administered: Flu
-
2021-09-29
Survey response — days 1–6 daily, dose 3MedDRA: Chest pain — Feeling: Poor · Site: Pain · Fever · Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Chest painMedDRA releases: 2024-11 · check-in free text available
-
2021-09-30
Survey response — days 1–6 daily, dose 3MedDRA: Lymph node pain, Lymphadenopathy — Feeling: Fair · Site: Pain · Be unable to do your normal daily activitiesFree text: Severe axillary lymphadenopathy- painful and largeMedDRA releases: 2024-11 · check-in free text available
-
2021-10-01
Survey response — days 1–6 daily, dose 3MedDRA: Lymph node pain, Lymphadenopathy — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Still very large, painful axillary lymphadenopathyMedDRA releases: 2024-11 · check-in free text available
-
2021-10-02
Survey response — days 1–6 daily, dose 3MedDRA: Lymph node pain, Lymphadenopathy — Feeling: FairFree text: Painful axillary lymphadenopathyMedDRA releases: 2024-11 · check-in free text available
-
2021-10-03
Survey response — days 1–6 daily, dose 3MedDRA: Lymphadenopathy — Feeling: GoodFree text: Axillary lymphadenopathyMedDRA releases: 2024-11 · check-in free text available
- 2021-10-07
- 2021-10-12
- 2021-10-21
- 2021-10-26
- 2021-11-02
- 2021-11-09
- 2021-12-28
- 2022-03-29
-
2022-09-16
Dose 4 — ModernaCo-administered: Flu
-
2022-09-17
Survey response — days 1–6 daily, dose 4MedDRA: Lymphadenopathy — Feeling: Poor · Site: Pain, Swelling · Fever · Headache, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Axillary lymphadenopathyMedDRA releases: 2024-11 · check-in free text available
-
2022-09-18
Survey response — days 1–6 daily, dose 4MedDRA: Lymphadenopathy, Oedema peripheral — Feeling: Fair · Site: PainFree text: Axillary swelling/lymphadenopathyMedDRA releases: 2024-11 · check-in free text available
-
2022-09-19
Survey response — days 1–6 daily, dose 4MedDRA: Lymphadenopathy — Feeling: Fair · Site: Swelling · Fatigue or tirednessFree text: Axillary lymphadenopathyMedDRA releases: 2024-11 · check-in free text available
- 2022-09-20
- 2022-09-21
- 2022-09-22
- 2022-09-23
- 2022-09-30
- 2022-10-07
- 2022-10-14
-
2022-10-21
Survey response — day 35, dose 4MedDRA: Viral upper respiratory tract infection — Feeling: FairFree text: Viral URIMedDRA releases: 2024-11 · check-in free text available
-
2022-10-28
Survey response — day 42, dose 4MedDRA: Viral upper respiratory tract infection — Feeling: Fair · Be unable to do your normal daily activitiesFree text: Viral URIMedDRA releases: 2024-11 · check-in free text available
- 2022-12-16
-
2023-03-17
Survey response — 6 months, dose 4MedDRA: Abortion spontaneous — Feeling: Fair · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Outpatient clinic or urgent care clinic visitMedDRA releases: 2024-11
-
2023-03-17
Report sent to call center — 6 months, dose 4Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prOutpatient clinic or urgent care clinic visit · 1 call case(s)
-
2023-03-20
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-20 | Pfizer-BioNTech | |
| 2 | 2021-01-10 | Pfizer-BioNTech | |
| 3 | 2021-09-28 | Pfizer-BioNTech | Flu |
| 4 | 2022-09-16 | Moderna | Flu |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2023-03-17 | Successful 2023-03-20 |
Not applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill |
Free text
Release 9 — days 1–6 daily, dose 3
Systemic reaction (other): Chest pain
Systemic reaction (other): Severe axillary lymphadenopathy- painful and large
Systemic reaction (other): Still very large, painful axillary lymphadenopathy
Systemic reaction (other): Painful axillary lymphadenopathy
Systemic reaction (other): Axillary lymphadenopathy
Release 12 — days 1–6 daily, dose 4
Systemic reaction (other): Axillary lymphadenopathy
Systemic reaction (other): Axillary swelling/lymphadenopathy
Systemic reaction (other): Axillary lymphadenopathy
Release 12 — day 35, dose 4
Symptoms: Viral URI
Release 12 — day 42, dose 4
Symptoms: Viral URI
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Abortion spontaneous | · | · | ✓ |
| SD | Viral upper respiratory tract infection | · | · | ✓ |
| SRO | Chest pain | · | · | ✓ |
| SRO | Lymph node pain | · | · | ✓ |
| SRO | Lymphadenopathy | · | · | ✓ |
| SRO | Oedema peripheral | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release